[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
In March 2022, [<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previou...
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
MDPI AG
2022-10-01
|
| Seri Bilgileri: | Pharmaceuticals |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1424-8247/15/10/1292 |